ClinicalTrials.gg
CompletedNCT03414684Updated Sep 9, 2026Results posted

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

A Phase 2 interventional study of Carboplatin and Nivolumab in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies testing nivolumab in Breast Neoplasms — 1 open to participants now, 8 under way, none of them phase 3. Nivolumab · Breast Neoplasms.

Enrollment
9th of 22
78 · median 47
Started
2018
with 2 others
Phase 2
15 of 22
1 open now
Registered
9th of 22
by date
Lead sponsor
3 of 22
Dana-Farber Cancer Institute

Among the 22 studies testing nivolumab in Breast Neoplasms, this one is the 9th largest by enrollment, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 9th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 22 studies testing nivolumab in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing nivolumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.

The interventions involved in this study are:

  • Carboplatin
  • Nivolumab
Read the detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved nivolumab for your specific disease but it has been approved for other uses. The FDA has approved carboplatin as a treatment option for your disease.

The purpose of this research study is to determine how well carboplatin, by itself, or together with nivolumab, works in treating breast cancer that has spread to other parts of the body. Nivolumab is a recently discovered human monoclonal antibody. An antibody is a type of protein that your immune system (the system that defends your body against potentially harmful particles) uses to find and destroy foreign molecules (particles not typically found in your body, such as bacteria and viruses). Scientists can now make antibodies in the laboratory and produce them for the treatment of many different diseases.

Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cell. Nivolumab has been shown in research studies to prevent PD-1 from shutting down the immune system, thus allowing it to recognize and help your body destroy the cancer cells. You are being asked to participate in this study because triple-negative breast cancer has shown elevated rates of PD-L1 expression.

Nivolumab has been used in other research studies and information from those research studies suggests that nivolumab may help shrink or stabilize your triple negative breast cancer in this study

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed invasive breast cancer, with unresectable locally advanced or disease. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation.
  • Estrogen-receptor and progesterone-receptor expression both ≤ 1% by immunohistochemistry (IHC), and -negative status as determined by the current ASCO/CAP guidelines. If a patient has more than one histological result, the most recent sample will be considered for inclusion.
  • Participants must have status available at the time of registration. Standard local testing with any PD-L1 antibody that has been validated in a CLIA-certified environment will be acceptable for including patients on trial.. Primary or metastatic samples may be tested for PD-L1 status.
  • Participants must have measurable or evaluable disease by version 1.1.
  • Participants must agree to undergo a research , if tumor is safely accessible, at baseline. Previously collected archival tissue will also be obtained on all participants. For participants for whom newly-obtained samples cannot be provided (e.g. inaccessible or participant safety concern) the archival tissue alone will be acceptable. Tissue needs to be located and availability confirmed at time of registration (See Section 9 for more details). Participants must agree to a mandatory repeat biopsy 3-6 weeks after starting treatment, if tumor is safely accessible. For patients randomized to carboplatin alone who decide to crossover to nivolumab and nab-paclitaxel at time of progression, a mandatory biopsy will be required if tumor is safely accessible prior to initiating crossover treatment; participants must also agree to undergo this biopsy, if applicable.
  • Prior chemotherapy: Participants must have received 0 prior chemotherapeutic regimens for metastatic breast cancer. Prior platinum in the neo/ setting is permissible, if at least 6 months elapsed since the end of adjuvant systemic therapy to the development of metastatic disease. All toxicities related to prior chemotherapy must have resolved to v4.0 grade 1 or lower, unless otherwise specified.
  • Prior biologic therapy: Prior poly-ADP ribose polymerase (PARP) inhibitors are not allowed in the metastatic setting. Prior PARP inhibitors in the neo/adjuvant setting are permissible, if at least 6 months elapsed since the end of adjuvant systemic therapy to the development of metastatic disease. All toxicities related to prior biologic therapy must have resolved to CTCAE v4.0 grade 1 or lower, unless otherwise specified.
  • Prior radiation therapy: Patients may have received prior radiation therapy. Radiation therapy must be completed at least 14 days prior to registration, and all toxicities related to prior radiation therapy must have resolved to CTCAE v4.0 grade 1 or lower, unless otherwise specified in 3.1.10. Patients may not have had >25% of their bone marrow radiated.
  • The subject is ≥18 years old.
  • performance status ≤1 ( >60%, see Appendix A).
  • Participants must have normal organ and marrow function as defined below:

    • ≥1,500/mcL
    • ≥100,000/mcL
    • ≥ 9.0 g/dl
    • Total ≤1.5 × institutional (ULN) (or ≤2.0 x ULN in patients with documented Gilbert's Syndrome)
    • (SGOT)/ALT(SGPT) ≤2.5 × institutional ULN or

      ≤5 × institutional ULN for participants with documented liver metastases

    • Serum creatinine ≤1.5 × institutional ULN OR ≥ 45 mL/min/ 1.73m2 for participants with creatinine levels above institutional ULN.
  • Supportive care (e.g. transfusion of red blood cells) is allowed to meet eligibility criteria.
  • Female subjects of must have a negative serum or urine pregnancy test within 2 weeks prior to registration.
  • Childbearing potential is defined as: participants who have not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus).
  • Women of childbearing potential (WOCBP) must agree to use an adequate method of . Contraception is required starting with the first dose of study medication through 150 days (5 months) after the last dose of study medication. Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab and 7 months after the last dose of study treatment (i.e., 90 days (duration of sperm turnover) plus the time required for the drug to undergo approximately five half-lives.)
  • Participants on bisphosphonates or RANK ligand inhibitors may continue receiving therapy during study treatment.
  • The participant must be capable of understanding and complying with the protocol and willing to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Concurrent administration of any other anti-cancer therapy during the course of this study (bisphosphonates and RANK ligand inhibitors are allowed).
  • Prior to platinum chemotherapy or to any of the of platinum or nivolumab therapy.
  • Prior therapy with an , anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  • Known that are untreated, symptomatic, or require therapy to control symptoms. Participants with a history of treated central nervous system (CNS) are eligible. Treated brain metastases are defined as those without ongoing requirement for , as ascertained by clinical examination and brain imaging (magnetic resonance imaging or CT scan) completed during screening. Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for ≥7 days prior to registration. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, surgery or a combination as deemed appropriate by the treating physician. Radiation therapy must be completed at least 7 days prior to registration
  • Major surgery within 2 weeks prior to registration. Patients must have recovered from any effects of any major surgery.
  • Uncontrolled, significant intercurrent or recent illness including, but not limited to, ongoing or active infection, uncontrolled non-malignant systemic disease, uncontrolled seizures, or psychiatric illness/social situation that would limit compliance with study requirements in the opinion of the treating investigator.
  • Participant has a medical condition that requires chronic systemic steroid therapy (> 10 mg of prednisone daily or equivalent) or any other form of medication (including disease modifying agents) and has required such therapy in the last 2 years. Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy.
  • Participant has documented history of disease or syndrome that currently requires systemic steroids or immunosuppressive agents.
  • History or evidence of active, non-infectious pneumonitis or interstitial lung disease.
  • Individuals with a history of a second are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers that have been diagnosed and treated within the past 3 years are eligible: cervical/prostate carcinoma in situ, superficial bladder cancer, non-melanoma cancer of the skin. Patients with other cancers diagnosed within the past 3 years and felt to be at low risk of recurrence should be discussed with the study sponsor to determine eligibility.
  • Participant is known to be positive for the (HIV), HepBsAg, or . HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions of combination antiretroviral therapy with study drugs. In addition, these participants are at increased risk of fatal infections when treated with marrow-suppressive therapy.
  • The participant has received a within 28 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. The use of the inactivated seasonal influenza vaccine is allowed.
  • Women who are pregnant or breastfeeding or adults of not employing an adequate method of .
  • is defined as: participants who have not reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus)
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Carboplatin + Nivolumab

    * Nivolumab is administered every three weeks intravenously * Nivolumab dosage is 360mg * Carboplatin is administered every three weeks intravenously * Carboplatin dosage is pre-determined by the PI

    Drug: Carboplatin · Drug: Nivolumab

  • Active comparator
    Carboplatin

    * Carboplatin is administered every three weeks intravenously * Carboplatin dosage is pre-determined by the PI

    Drug: Carboplatin

Interventions

  • Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.

  • Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Defined as the time from randomization to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation

    Time frame: Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years

Secondary outcomes

  1. Objective Response Rate by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1

    Defined as the percentage of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  2. Objective Response Rate by Immune-Related Response Criteria (irRC)

    Defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  3. Overall Survival

    Defined as the time from randomization to death due to any cause, or censored at date last known alive

    Time frame: Assessed from date of randomization until the date of death from any cause, up to 3.5 years

  4. Clinical Benefit Rate

    Defined as the proportion of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  5. Duration of Response

    Defined as the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Patients without events reported are censored at the last disease evaluation.

    Time frame: Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 2.75 years

  6. Time to Objective Response

    Defined as the time from randomization to the date of the first documented CR or PR by RECIST 1.1, whichever is first recorded

    Time frame: Assessed from randomization to the time of first response, up to 3.5 years

  7. Progression-free Survival Among PD-L1-positive Patients

    PFS defined as the time from randomization to the earlier of progression or death due to any cause; participants alive without disease progression are censored at date of last disease evaluation. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

    Time frame: Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years

  8. Objective Response Rate by RECIST 1.1 Among PD-L1-positive Patients

    ORR defined as the proportion of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  9. Objective Response Rate by irRC Among PD-L1-positive Patients

    ORR by irRC defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  10. Overall Survival Among PD-L1-positive Patients

    OS defined as the time from randomization to death due to any cause, or censored at date last known alive. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

    Time frame: Assessed from date of randomization until the date of death from any cause, up to 3.5 years

  11. Clinical Benefit Rate Among PD-L1-positive Patients

    CBR defined as the proportion of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  12. Duration of Response Among PD-L1-positive Patients

    DOR defined as the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Patients without events reported are censored at the last disease evaluation. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

    Time frame: Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 2.75 years

  13. Time to Objective Response Among PD-L1-positive Patients

    TTOR defined as the time from randomization to the date of the first documented CR or PR by RECIST 1.1, whichever is first recorded. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

    Time frame: Assessed from randomization to the time of first response, up to 3.5 years

  14. Second-course Progression-free Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

    PFS defined as the time from the start of crossover treatment to the earlier of progression (on crossover therapy) or death due to any cause; participants alive without disease progression are censored at date of last disease evaluation.

    Time frame: Assessed from the start of crossover therapy to the date of first documented progression on crossover therapy or the date of death from any cause, whichever came first, up to 2.8 years

  15. Second-course Objective Response Rate by RECIST 1.1 Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

    ORR defined as the proportion of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1., during crossover therapy

    Time frame: Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years

  16. Second-course Objective Response Rate by irRC Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

    ORR by irRC defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC, during second-course therapy

    Time frame: Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years

  17. Second-course Clinical Benefit Rate Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

    CBR defined as the proportion of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks, during second course therapy

    Time frame: Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years

  18. Second-course Duration of Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

    DOR defined as the time measurement criteria are met for second-course CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented thereafter. Patients without events reported are censored at the last disease evaluation.

    Time frame: Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) on crossover therapy to the time of first progression on crossover therapy, up to 2.5 years

  19. Second-course Time to Objective Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

    TTOR defined as the time from start of crossover treatment to the date of the first documented CR or PR by RECIST 1.1 on second-course therapy, whichever is first recorded

    Time frame: Assessed from the start of crossover therapy to the time of first response on crossover therapy, up to 2.8 years

  20. Second-course Overall Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

    Second-course OS defined as the time from the start of crossover treatment to death due from any cause, or censored at date last known alive.

    Time frame: Assessed from the start of crossover therapy until the date of death from any cause, up to 2.8 years

  21. Progression-free Survival Among BRCA-mutant Patients

    PFS defined as the time from randomization to the earlier of progression or death due to any cause; participants alive without disease progression are censored at date of last disease evaluation. BRCA-mutant patients were those having BRCA1 or BRCA2 mutations.

    Time frame: Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years

  22. Objective Response Rate by RECIST 1.1 Among BRCA-mutant Patients

    ORR defined as the proportion of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  23. Objective Response Rate by irRC Among BRCA-mutant Patients

    ORR by irRC defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  24. Overall Survival Among BRCA-mutant Patients

    OS defined as the time from randomization to death due to any cause, or censored at date last known alive. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

    Time frame: From date of randomization until the date of death from any cause, assessed up to 3.5 years

  25. Clinical Benefit Rate Among BRCA-mutant Patients

    CBR defined as the percentage of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

    Time frame: Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years

  26. Duration of Response Among BRCA-mutant Patients

    DOR defined as the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Patients without events reported are censored at the last disease evaluation. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

    Time frame: Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 3.5 years

  27. Time to Objective Response Among BRCA-mutant Patients

    TTOR defined as the time from randomization to the date of the first documented CR or PR by RECIST 1.1, whichever is first recorded. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

    Time frame: Assessed from randomization to the time of first response, up to 3.5 years

07

Results

Posted Jan 26, 2023

Participant flow

The first patient was enrolled on February 12, 2018, and the last patient was enrolled on September 23, 2020.

First-course treatment
Participant flow — First-course treatment
MilestoneArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Started3939
Started treatment3738
Completed00
Not completed3939
Withdrew: Complete response01
Withdrew: Intercurrent illness10
Withdrew: Progressive disease3132
Withdrew: Adverse event12
Withdrew: Physician decision01
Withdrew: Withdrawal by subject01
Withdrew: "patient proceeded with chest wall excision"10
Withdrew: "participant needed palliative radiation, which is not permitted on study"01
Withdrew: Still on treatment30
Withdrew: Never started protocol therapy21
Crossover treatment
Participant flow — Crossover treatment
MilestoneArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Started018
Completed00
Not completed018
Withdrew: Progressive disease012
Withdrew: Adverse event03
Withdrew: Physician decision01
Withdrew: Still on treatment02

Outcome measures

PrimaryProgression-free Survival

Defined as the time from randomization to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation

Time frame:
Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years
Reported as:
Median · months
Progression-free Survival
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Progression-free Survival4.2 (2.7 to 11.5)5.5 (4.4 to 19.2)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Log Rank · p = 0.88 · Hazard ratio (hr): 0.95 · 95% CI 0.49 to 1.84Reference level is Arm B, such that hazard ratio corresponds to the effect of treatment on Arm A
SecondaryObjective Response Rate by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1

Defined as the percentage of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Objective Response Rate by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Objective Response Rate by Response Evaluation Criteria in Solid Tumours (RECIST) 1.125.0 (11.5 to 43.4)23.3 (9.9 to 42.3)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Fisher Exact · p = 1 · Odds ratio (or): 1.09 · 95% CI 0.29 to 4.18Reference level is Arm B, such that the odds ratio corresponds to the effect of treatment on Arm A
SecondaryObjective Response Rate by Immune-Related Response Criteria (irRC)

Defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Objective Response Rate by Immune-Related Response Criteria (irRC)
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Objective Response Rate by Immune-Related Response Criteria (irRC)28.1 (13.7 to 46.7)—
SecondaryOverall Survival

Defined as the time from randomization to death due to any cause, or censored at date last known alive

Time frame:
Assessed from date of randomization until the date of death from any cause, up to 3.5 years
Reported as:
Median · months
Overall Survival
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Overall Survival16.8 (10.4 to NA)11.1 (8.2 to 24.4)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Log Rank · p = 0.49 · Hazard ratio (hr): 0.80 · 95% CI 0.43 to 1.50Reference level is Arm B, such that the hazard ratio corresponds to treatment on Arm A
SecondaryClinical Benefit Rate

Defined as the proportion of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Clinical Benefit Rate
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Clinical Benefit Rate34.4 (18.6 to 53.2)33.3 (17.3 to 52.8)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Fisher Exact · p = 1 · Odds ratio (or): 1.05 · 95% CI 0.32 to 3.43Reference level is Arm B, such that the odds ratio corresponds to treatment on Arm A
SecondaryDuration of Response

Defined as the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Patients without events reported are censored at the last disease evaluation.

Time frame:
Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 2.75 years
Reported as:
Median · months
Duration of Response
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Duration of Response19.3 (16.8 to NA)7.7 (2.7 to NA)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Log Rank · p = 0.36 · Hazard ratio (hr): 0.53 · 95% CI 0.13 to 2.12Reference level is Arm B, such that the hazard ratio corresponds to treatment on Arm A
SecondaryTime to Objective Response

Defined as the time from randomization to the date of the first documented CR or PR by RECIST 1.1, whichever is first recorded

Time frame:
Assessed from randomization to the time of first response, up to 3.5 years
Reported as:
Median · months
Time to Objective Response
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Time to Objective Response4.6 (4.0 to NA)11.2 (4.7 to NA)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Log Rank · p = 0.68 · Hazard ratio (hr): 1.24 · 95% CI 0.43 to 3.43Reference level is Arm B, such that the hazard ratio corresponds to treatment on Arm A
SecondaryProgression-free Survival Among PD-L1-positive Patients

PFS defined as the time from randomization to the earlier of progression or death due to any cause; participants alive without disease progression are censored at date of last disease evaluation. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

Time frame:
Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years
Reported as:
Median · months
Progression-free Survival Among PD-L1-positive Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Progression-free Survival Among PD-L1-positive Patients8.3 (2.5 to NA)4.7 (1.6 to NA)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Log Rank · p = 0.27 · Hazard ratio (hr): 0.54 · 95% CI 0.18 to 1.62Reference level is Arm B, such that the hazard ratio corresponds to treatment on Arm A
SecondaryObjective Response Rate by RECIST 1.1 Among PD-L1-positive Patients

ORR defined as the proportion of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Objective Response Rate by RECIST 1.1 Among PD-L1-positive Patients
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Objective Response Rate by RECIST 1.1 Among PD-L1-positive Patients23.1 (5.0 to 53.8)27.3 (6.0 to 61.0)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Fisher Exact · p = 1 · Odds ratio (or): 0.81 · 95% CI 0.08 to 7.78Reference level is Arm B, such that the odds ratio corresponds to treatment on Arm A
SecondaryObjective Response Rate by irRC Among PD-L1-positive Patients

ORR by irRC defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Objective Response Rate by irRC Among PD-L1-positive Patients
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Objective Response Rate by irRC Among PD-L1-positive Patients30.8 (9.1 to 61.4)—
SecondaryOverall Survival Among PD-L1-positive Patients

OS defined as the time from randomization to death due to any cause, or censored at date last known alive. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

Time frame:
Assessed from date of randomization until the date of death from any cause, up to 3.5 years
Reported as:
Median · months
Overall Survival Among PD-L1-positive Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Overall Survival Among PD-L1-positive Patients17.6 (4.9 to NA)10.7 (6.7 to NA)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Log Rank · p = 0.61 · Hazard ratio (hr): 0.75 · 95% CI 0.26 to 2.16Reference level is Arm B, such that the hazard ratio corresponds to treatment on Arm A
SecondaryClinical Benefit Rate Among PD-L1-positive Patients

CBR defined as the proportion of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Clinical Benefit Rate Among PD-L1-positive Patients
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Clinical Benefit Rate Among PD-L1-positive Patients30.8 (9.1 to 61.4)36.4 (10.9 to 69.2)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Fisher Exact · p = 1 · Odds ratio (or): 0.79 · 95% CI 0.10 to 5.93Reference level is Arm B, such that the odds ratio corresponds to treatment on Arm A
SecondaryDuration of Response Among PD-L1-positive Patients

DOR defined as the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Patients without events reported are censored at the last disease evaluation. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

Time frame:
Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 2.75 years
Reported as:
Median · months
Duration of Response Among PD-L1-positive Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Duration of Response Among PD-L1-positive Patients16.8 (NA to NA)4.9 (2.0 to NA)
SecondaryTime to Objective Response Among PD-L1-positive Patients

TTOR defined as the time from randomization to the date of the first documented CR or PR by RECIST 1.1, whichever is first recorded. PD-L1 positivity defined as ≥1% of the tumor cell population demonstrating unequivocal staining for PD-L1.

Time frame:
Assessed from randomization to the time of first response, up to 3.5 years
Reported as:
Median · months
Time to Objective Response Among PD-L1-positive Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Time to Objective Response Among PD-L1-positive PatientsNA (3.4 to NA)NA (3.0 to NA)
Statistical analysis
  • Arm A: Carboplatin + Nivolumab vs Arm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion · Log Rank · p = 0.73 · Hazard ratio (hr): 0.75 · 95% CI 0.14 to 3.89Reference level is Arm B, such that the hazard ratio corresponds to treatment on Arm A
SecondarySecond-course Progression-free Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

PFS defined as the time from the start of crossover treatment to the earlier of progression (on crossover therapy) or death due to any cause; participants alive without disease progression are censored at date of last disease evaluation.

Time frame:
Assessed from the start of crossover therapy to the date of first documented progression on crossover therapy or the date of death from any cause, whichever came first, up to 2.8 years
Reported as:
Median · months
Second-course Progression-free Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Second-course Progression-free Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab—4.1 (1.9 to NA)
SecondarySecond-course Objective Response Rate by RECIST 1.1 Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

ORR defined as the proportion of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1., during crossover therapy

Time frame:
Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years
Reported as:
Number · percent of patients
Second-course Objective Response Rate by RECIST 1.1 Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Second-course Objective Response Rate by RECIST 1.1 Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab—20.0 (2.5 to 55.6)
SecondarySecond-course Objective Response Rate by irRC Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

ORR by irRC defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC, during second-course therapy

Time frame:
Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years
Reported as:
Number · percent of patients
Second-course Objective Response Rate by irRC Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Second-course Objective Response Rate by irRC Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab—20.0 (2.5 to 55.6)
SecondarySecond-course Clinical Benefit Rate Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

CBR defined as the proportion of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks, during second course therapy

Time frame:
Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years
Reported as:
Number · percent of patients
Second-course Clinical Benefit Rate Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Second-course Clinical Benefit Rate Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab—30.0 (6.7 to 65.2)
SecondarySecond-course Duration of Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

DOR defined as the time measurement criteria are met for second-course CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented thereafter. Patients without events reported are censored at the last disease evaluation.

Time frame:
Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) on crossover therapy to the time of first progression on crossover therapy, up to 2.5 years
Reported as:
Median · months
Second-course Duration of Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Second-course Duration of Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab—1.81 (1.81 to NA)
SecondarySecond-course Time to Objective Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

TTOR defined as the time from start of crossover treatment to the date of the first documented CR or PR by RECIST 1.1 on second-course therapy, whichever is first recorded

Time frame:
Assessed from the start of crossover therapy to the time of first response on crossover therapy, up to 2.8 years
Reported as:
Median · months
Second-course Time to Objective Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Second-course Time to Objective Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab—NA (3.5 to NA)
SecondarySecond-course Overall Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab

Second-course OS defined as the time from the start of crossover treatment to death due from any cause, or censored at date last known alive.

Time frame:
Assessed from the start of crossover therapy until the date of death from any cause, up to 2.8 years
Reported as:
Median · months
Second-course Overall Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Second-course Overall Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab—12.9 (6.4 to NA)
SecondaryProgression-free Survival Among BRCA-mutant Patients

PFS defined as the time from randomization to the earlier of progression or death due to any cause; participants alive without disease progression are censored at date of last disease evaluation. BRCA-mutant patients were those having BRCA1 or BRCA2 mutations.

Time frame:
Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years
Reported as:
Median · months
Progression-free Survival Among BRCA-mutant Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Progression-free Survival Among BRCA-mutant Patients—4.74 (4.74 to NA)
SecondaryObjective Response Rate by RECIST 1.1 Among BRCA-mutant Patients

ORR defined as the proportion of patients achieving a complete response (complete disappearance of all target and non-target lesions; no new lesions) or partial response (at least 30% decrease in the sum of the diameters of target lesions; persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits \[i.e., "non-CR/non-PD" in non-target lesions\]; and no new lesions) based on RECIST 1.1. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Objective Response Rate by RECIST 1.1 Among BRCA-mutant Patients
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Objective Response Rate by RECIST 1.1 Among BRCA-mutant Patients—50.0 (1.3 to 98.7)
SecondaryObjective Response Rate by irRC Among BRCA-mutant Patients

ORR by irRC defined as the proportion of patients achieving an immune-related complete response (complete disappearance of all target and non-target lesions; no new measurable/unmeasurable lesions) or immune-related partial response (a decrease of the immune-related sum of product diameters \[irSPD\] of 50% or greater) based on irRC. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number

No measurements were reported for this outcome.

SecondaryOverall Survival Among BRCA-mutant Patients

OS defined as the time from randomization to death due to any cause, or censored at date last known alive. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

Time frame:
From date of randomization until the date of death from any cause, assessed up to 3.5 years
Reported as:
Median · months
Overall Survival Among BRCA-mutant Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Overall Survival Among BRCA-mutant Patients—24.4 (NA to NA)
SecondaryClinical Benefit Rate Among BRCA-mutant Patients

CBR defined as the percentage of patients achieving a complete response or partial response by RECIST 1.1, or stable disease lasting greater than or equal to 24 weeks. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

Time frame:
Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years
Reported as:
Number · percent of patients
Clinical Benefit Rate Among BRCA-mutant Patients
percent of patientsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Clinical Benefit Rate Among BRCA-mutant Patients—50.0 (1.3 to 98.7)
SecondaryDuration of Response Among BRCA-mutant Patients

DOR defined as the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Patients without events reported are censored at the last disease evaluation. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

Time frame:
Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 3.5 years
Reported as:
Median · months
Duration of Response Among BRCA-mutant Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Duration of Response Among BRCA-mutant Patients—2.04 (NA to NA)
SecondaryTime to Objective Response Among BRCA-mutant Patients

TTOR defined as the time from randomization to the date of the first documented CR or PR by RECIST 1.1, whichever is first recorded. BRCA-mutant patients were those with BRCA1 or BRCA2 mutations.

Time frame:
Assessed from randomization to the time of first response, up to 3.5 years
Reported as:
Median · months
Time to Objective Response Among BRCA-mutant Patients
monthsArm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician Discretion
Time to Objective Response Among BRCA-mutant Patients—3.2 (3.2 to NA)

Adverse events

Collected over Adverse event data were collected on the first day of each cycle of treatment, as well as at the end of treatment, for both arms, up to 3.5 years. Additionally, patients on Arm A and crossover patients (only) had an adverse events assessment 100 days (-15/+30 days) after the last dose of nivolumab, up to 3.5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Carboplatin + Nivolumab24/37 (64.9%)10/37 (27%)37/37 (100%)
Arm B: Carboplatin17/38 (44.7%)11/38 (28.9%)38/38 (100%)
Arm B: Carboplatin -- Crossover10/18 (55.6%)6/18 (33.3%)18/18 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventArm A: Carboplatin + NivolumabArm B: CarboplatinArm B: Carboplatin -- Crossover
Platelet count decreasedInvestigations3/371/382/18
Lung infectionInfections and infestations1/371/381/18
SepsisInfections and infestations1/370/381/18
Blood bilirubin increasedInvestigations1/370/381/18
HypoxiaRespiratory, thoracic and mediastinal disorders2/372/381/18
PainGeneral disorders0/372/381/18
Pleural effusionRespiratory, thoracic and mediastinal disorders0/371/381/18
EnterocolitisGastrointestinal disorders0/370/381/18
Small intestinal obstructionGastrointestinal disorders0/370/381/18
Flu like symptomsGeneral disorders0/370/381/18
Most frequent other events
Showing 10 of 102
Most frequent other events
EventArm A: Carboplatin + NivolumabArm B: CarboplatinArm B: Carboplatin -- Crossover
Platelet count decreasedInvestigations29/3720/385/18
FatigueGeneral disorders28/3728/3811/18
NauseaGastrointestinal disorders21/3726/387/18
AnemiaBlood and lymphatic system disorders25/3720/388/18
Neutrophil count decreasedInvestigations20/3721/387/18
DiarrheaGastrointestinal disorders11/377/389/18
ConstipationGastrointestinal disorders18/3714/384/18
DyspneaRespiratory, thoracic and mediastinal disorders15/3717/387/18
Peripheral sensory neuropathyNervous system disorders15/3711/386/18
PainGeneral disorders10/3713/384/18

Baseline characteristics

78 patients were enrolled and randomized, but only 75 patients started protocol therapy. The primary analysis population is the treated population, thus baseline characteristics are shown for the 75 patients that started protocol therapy.

Age, Continuous
Age, Continuous(years)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
Median59.1 (27.9 to 75.8)59.1 (25.4 to 75.5)59.1 (25.4 to 75.8)
Age, Customized
Age, Customized(Participants)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
Age, years — <40145
Age, years — 40-59191635
Age, years — >=60171835
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
Female373875
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
Hispanic or Latino202
Not Hispanic or Latino333669
Unknown or Not Reported224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
Asian101
Black or African American235
Caucasian303464
More than one race112
Other303
Germline BRCA Status
Germline BRCA Status(Participants)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
gBRCA1 mutation123
gBRCA2 mutation011
Non-gBRCA1/2 carrier363571
Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) Status -- Local
Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) Status -- Local(Participants)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
Positive6612
Negative111223
Not done202040
Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) Status -- Central, SP142
Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) Status -- Central, SP142(Participants)Arm A: Carboplatin + NivolumabArm B: Carboplatin, Then Nivolumab +/- Nab-paclitaxel After Progression, Per Physician DiscretionTotal
Positive (>=1% IC)141428
Negative (<1% IC)232447

8 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • The Stamford Hospital
    Stamford, Connecticut 06904, United States
  • Eastern Maine Medical Center
    Bangor, Maine 04401, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • St. Elizabeth's Medical Center
    Boston, Massachusetts 02135, United States
  • Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
    Milford, Massachusetts 01757, United States
  • Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
    South Weymouth, Massachusetts 02190, United States
  • Dana-Farber/New Hampshire Oncology-Hematology
    Londonderry, New Hampshire 03053, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Sep 2021, 43 months.

Results were first posted in Jan 2023, 1 year 3 months after primary completion.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 43 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2017
First posted
Jan 30, 2018
StartActual
Jan 30, 2018
Primary completionActual
Sep 28, 2021
CompletionActual
Aug 5, 2026
Results first posted
Jan 26, 2023
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03414684
Responsible party
Sara Tolaney, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jan 30, 2018
Start date
Jan 30, 2018
Primary completion
Sep 28, 2021
Completion
Aug 5, 2026
Results posted
Jan 26, 2023
Last update
Sep 9, 2026

Study contacts

Sara Tolaney, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion